A short synthetic peptide studied in animal models for tissue repair and recovery. Interest is real; regulatory status is clear. Here’s what the evidence supports, what it doesn’t, and what the current legal picture is.
Regulatory notice: BPC-157 is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. Its status is in active transition: on July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review BPC-157 for addition to the list. Any recommendation from that committee is non-binding, and FDA has not issued a final determination.
This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.
BPC-157, “body protection compound”, is a 15-amino-acid synthetic peptide corresponding to a fragment of a larger protein isolated from human gastric juice. It was first described in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, and the same research group has produced the majority of the published literature on it across the three decades since.
Unlike most peptides that mimic a single hormone or bind a single receptor, BPC-157 appears to operate through multiple biological pathways, modulation of growth-factor signaling (VEGF, EGF, bFGF), nitric-oxide pathway effects, and interactions with the dopaminergic and serotonergic systems. No single receptor has been established as the primary target; the literature describes it as broadly cytoprotective. It is also unusual in showing activity via both injection and oral administration in animal models, which is uncommon for peptide compounds.
Four pathways recur across the preclinical literature. None are confirmed in large-scale, independent human trials.
Sikiric et al. (2006, Journal of Physiology Paris) demonstrated that BPC-157 promotes new blood-vessel formation in damaged tissue in rat models. The effect was mediated through VEGF upregulation, potentially improving nutrient delivery to repair sites.
Sikiric et al. (2014, Molecules) reported that BPC-157 may upregulate growth-hormone-receptor expression in animal models. Interaction with the GH/IGF-1 axis remains an active area of investigation.
A series of studies reviewed in 2016 (Current Pharmaceutical Design) showed BPC-157 interacting bidirectionally with the nitric-oxide system in rat models, counteracting both NO-synthase inhibition and excess NO, consistent with a modulatory role on blood-flow and inflammation signaling.
Multiple publications from the Zagreb group (1993–2020s) report anti-inflammatory activity through several pathways, including effects on TNF-α and IL-6 in animal injury models. Exact mechanisms are still being characterized.
These mechanisms are based on preclinical and animal research, primarily from a single research group. None have been confirmed through large-scale, independent human trials.
The published BPC-157 evidence base is dominated by animal studies, the bulk of them from the Sikiric group at the University of Zagreb. Human clinical trial data is limited. Below are the four areas where the preclinical signal is strongest.
Chang et al. (2003, Journal of Orthopaedic Research) found that BPC-157 accelerated tendon-to-bone healing in a rat Achilles tendon model. Krivic et al. (2010, Journal of Orthopaedic Surgery and Research) reported improved tendon-healing outcomes versus controls. Neither finding has been replicated in human trials.
Given its origin in gastric proteins, BPC-157 has been extensively studied for GI-protective effects. Sikiric et al. published a foundational 1993 paper (Journal of Physiology Paris) showing mucosal protection against ethanol- and NSAID-induced damage in rats. Subsequent work (2012–2020, Current Pharmaceutical Design) extended cytoprotection across several GI injury models.
Pevec et al. (2010, Journal of Physiology Paris) reported improved muscle healing in rat crush-injury models treated with BPC-157, with the proposed mechanism involving angiogenesis and growth-factor modulation. A 2019 review (Current Pharmaceutical Design) summarized the preclinical muscle-repair literature; human data is still absent.
Preclinical work in Current Neuropharmacology (2018) and Current Pharmaceutical Design (2020) reported neuroprotective effects in animal models of drug-induced neurotoxicity, including protection against dopaminergic damage. This is the earliest-stage area of the BPC-157 literature and is not characterized in humans.
In published research, BPC-157 has been studied via subcutaneous injection and oral capsule administration. Both routes have shown activity in animal models, though bioavailability and optimal dosing have not been established through human pharmacokinetic studies.
Dosing in research contexts varies widely. There is no established human protocol from regulatory-grade clinical trials, and no consensus dose-finding across the preclinical literature.
This is research context, not prescribing guidance. BPC-157 is handled consultation-first, and the information on this page should not be interpreted as a dosing recommendation.
The honest read: human safety data on BPC-157 is thin. Here’s what exists.
In the available preclinical data, BPC-157 has shown a favorable safety profile across a range of doses. Xu et al. (2020, Regulatory Toxicology and Pharmacology) reported that no LD50 could be established in rodents; single-dose rat studies up to 20 mg/kg produced no mortality and no general-signs abnormalities over 14-day follow-up. BPC-157 was also well tolerated in mice, rabbits, and dogs across separate preclinical evaluations.
There are no large-scale, peer-reviewed human safety trials for BPC-157. Most safety inferences are drawn from animal models and anecdotal reports, an important limitation. A Phase I trial for ulcerative colitis (NCT04465890) was registered on ClinicalTrials.gov, but results have not been published in peer-reviewed literature as of April 2026.
Educational information; not medical advice. Talk to a licensed clinician before considering any peptide therapy.
BPC-157 was placed on the FDA’s Category 2 list of bulk drug substances in September 2023. It is not currently on FDA’s 503A Bulks List, and FDA has issued no final determination since its Pharmacy Compounding Advisory Committee met to review BPC-157 on July 23–24, 2026.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including BPC-157. That announcement has not been formally published in the Federal Register and carries no legal effect until it is.
Gray-market “research chemical” vendors sell substances labeled as BPC-157, but those products are unregulated. Their purity, potency, and identity cannot be verified by consumers, and they carry separate risks unrelated to the compound itself.
Available alternatives
Recovery, tissue support, and cellular repair, through legally available, 503A-compounded peptides prescribed by a licensed clinician.
Looking for a clinician-led recovery protocol that doesn’t commit you to a specific peptide up front? Take the assessment and a clinician will recommend the right protocol.
Deep dives
Research-backed articles covering specific topics in depth.
The uses commenters bring to a single recovery thread stretch from post-surgical rotator cuff to spinal stenosis, scoliosis and carpal tunnel, with one reporting grip strength returning and another predicting nothing will help him. That breadth is the tell, since no human trial defines which of those conditions, if any, BPC-157 affects, and it remains unapproved and absent from FDA's 503A Bulks List.
Posted on Reddit
BPC-157 is not currently on FDA's 503A Bulks List. PepScribe's programs put a clinician in the loop to review your recovery goals and the options open to you.
